Diabetes drug metformin may boost lung function in CF patients

NCT ID NCT04530383

Recruiting now Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial is testing whether metformin, a common diabetes drug, can improve airway function in 30 adults with cystic fibrosis-related diabetes who are already on CFTR modulator therapy. Researchers will measure changes in ion channel activity in nasal cells. The study aims to see if metformin can help control both blood sugar and lung health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin (Glucophage)
What this could lead to: If it works, this could point toward a way to improve lung function in people with cystic fibrosis-related diabetes.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. Metformin can cause side effects like stomach upset.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis cystic fibrosis-related diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS CYSTIC FIBROSIS RELATED DIABETES

Contacts and locations

Locations

University of Kansas Medical Center
RECRUITING

Kansas City, Kansas, 66160, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.